Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0125 | 0.0101 | 0.0155 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.00562 | 0.00408 | 0.00774 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0069 | 0.00368 | 0.0103 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 2.23 | 1.51 | 3.28 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 2.24 | 1.52 | 3.31 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Ticagrelor 90 mg than on ASA 100 mg | 145 | 97.4 | 272 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Ticagrelor 90 mg | Ticagrelor 90 mg twice daily (BD) | 82 | 6,549 | OG000 | ClinicalTrials.gov |
| Group 2 | ASA 100 mg | ASA 100 mg once daily (OD) | 37 | 6,581 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event | ClinicalTrials.gov |
| Description | Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). | ClinicalTrials.gov |
| Time frame | Time from first dose and up to and including 7 days following the date of last dose of the study | ClinicalTrials.gov |
| Population | The population was the safety analysis set, which included all patients who received at least 1 dose of randomized ticagrelor or ASA and for whom post-dose data are available. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] | ClinicalTrials.gov |
| NCT number | NCT01994720 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Acute Ischaemic Stroke, Transient Ischaemic Attack | ClinicalTrials.gov |
| Interventions | ticagrelor, Acetylsalicylic acid (ASA) | ClinicalTrials.gov |
| Lead sponsor | AstraZeneca | ClinicalTrials.gov |
| Results first posted | 2017-06-12 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01994720?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.